Studies on the once daily dosing immunosuppressive therapy of tacrolimus extended release and mycophenolate mofetil in maintenance kidney transplant patients

Studies on the once daily dosing immunosuppressive therapy of tacrolimus extended release and mycophenolate mofetil in maintenance kidney transplant patients - Studies on the once daily dosing immunosuppressive therapy of tacrolimus extended release and mycophenolate mofetil

Status

Active, not recruiting

Phases

Phase 4

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000008985

Enrollment

Registered

2012-09-26

Start date

2012-09-27

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Chronic renal failure

Interventions

once daily administration of mycophenolate mofetil

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: patients who underwent kidney transplant surgery more than 1 year ago patients in stable general condition patients who take tacrolimus, mycophenlate mofetil and steroid patients who take 1000mg or less mycophenlate mofetil per day patients with written informed consent

Exclusion criteria

Exclusion criteria: patiens with liver dysfunction

Design outcomes

Primary

Measure	Time frame
acute rejection rate during 3 months before and 3months after swiching	—

Secondary

Measure	Time frame
serum creatinine level during 3 months before and 3months after swiching	—

Countries

Japan

Contacts

Public ContactNaotsugu Ichimaru

Osaka University Graduate School of Medicine Department of Advanced Technology for Transplantation

+81-6-6879-3746

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026